Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
暂无分享,去创建一个
J. Kładny | J. Lubiński | S. Narod | C. Cybulski | T. Byrski | T. Huzarski | J. Gronwald | R. Dent | B. Górski | S. Narod | R. Dent | D. Zuziak | S. A. Narod
[1] G. Mills,et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. , 2008, Cancer research.
[2] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Winer,et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Warren,et al. BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials , 2007, Clinical Cancer Research.
[5] Ofra Barnett-Griness,et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. , 2007, The New England journal of medicine.
[6] M. Privat,et al. BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel Resistance , 2006, Cell cycle.
[7] A. Ashworth,et al. Targeting the DNA repair defect of BRCA tumours. , 2005, Current opinion in pharmacology.
[8] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Johnston,et al. The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.
[10] A. Jakubowska,et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families , 2004, International journal of cancer.
[11] O. Olopade,et al. Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.
[12] S. Sundar,et al. Platinum-based chemotherapy in metastatic breast cancer: current status. , 2004, Cancer treatment reviews.
[13] J. Satagopan,et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.
[14] P. Johnston,et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.
[15] R. L. Baldwin,et al. Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.
[16] Jinsong Liu,et al. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1 , 2003, Oncogene.
[17] R. Weichselbaum,et al. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.
[18] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.
[19] J. Sainsbury,et al. ABC of breast diseases , 2000 .
[20] M. Uslenghi,et al. The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.